[{"id":"5c88c63c-d256-4f58-81e6-5b70704df6d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06632262","created_at":"2025-02-26T15:04:35.295Z","updated_at":"2025-02-26T15:04:35.295Z","phase":"Phase 2","brief_title":"A Phase 2 Clinical Study of ABSK061 and ABSK043","source_id_and_acronym":"NCT06632262","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" HER-2 • FGFR2 • FGFR3","pipe":"","alterations":" ","tags":["HER-2 • FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK043 • lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 11/13/2024","start_date":" 11/13/2024","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-11-19"},{"id":"e8b52408-b9f1-495a-aa7b-39ffa9ebc874","acronym":"","url":"https://clinicaltrials.gov/study/NCT04964375","created_at":"2021-07-16T13:53:11.713Z","updated_at":"2024-07-02T16:36:11.411Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT04964375","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK043"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 10/23/2022","primary_completion_date":" 10/23/2022","study_txt":" Completion: 03/23/2023","study_completion_date":" 03/23/2023","last_update_posted":"2022-04-27"}]